Short Interest in Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Expands By 265.0%

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZNGet Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 7,300 shares, a growth of 265.0% from the March 31st total of 2,000 shares. Based on an average trading volume of 58,700 shares, the short-interest ratio is currently 0.1 days.

Shares of OTCMKTS ENZN opened at $0.32 on Thursday. The business’s 50 day moving average price is $0.32 and its 200 day moving average price is $0.34. The firm has a market cap of $23.39 million, a P/E ratio of -7.88 and a beta of 0.06. Enzon Pharmaceuticals has a 52 week low of $0.25 and a 52 week high of $0.76.

About Enzon Pharmaceuticals (Get Rating)

Enzon Pharmaceuticals, Inc, together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Featured Stories

Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.